Midazolam drug detail about mechanism uses dosage in specific condition complications and all
Reading File
Finding Sources
Searching PubMed
midazolam sedation pharmacology clinical use
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from multiple authoritative sources. Let me compile the full, detailed response.
Midazolam - Complete Drug Reference
Drug Class & Overview
Midazolam is a short-acting benzodiazepine (imidazobenzodiazepine subtype). Unlike older benzodiazepines, it has a fused imidazole ring that makes it water-soluble at acidic pH (useful for parenteral formulation) but lipid-soluble at physiologic pH (enabling rapid CNS penetration). It is 3-6 times more potent than diazepam.
- Brand names: Versed (discontinued), Nayzilam (intranasal)
- Formulations: Injection (1 mg/mL, 5 mg/mL), Oral syrup (2 mg/mL), Intranasal solution (5 mg/0.1 mL)
Mechanism of Action
Midazolam acts as a positive allosteric modulator at GABA-A receptors (ionotropic chloride channels). It binds to the benzodiazepine site at the interface of the alpha and gamma subunits, increasing the frequency of chloride channel opening in response to GABA. This causes neuronal hyperpolarization, reducing neuronal excitability throughout the CNS.
Subunit-specific effects (Goldman-Cecil Medicine; Miller's Anesthesia):
| Effect | GABA-A Subunit |
|---|---|
| Sedation, anterograde amnesia, anticonvulsant | alpha-1 subunit |
| Anxiolysis, muscle relaxation | alpha-2 subunit |
Key points:
- Only 20% receptor occupancy is needed for anxiolysis; 60% occupancy is required for unconsciousness
- Benzodiazepines do not activate GABA-A receptors alone - they only enhance GABA's effect (ceiling effect on CNS depression vs. barbiturates)
- No analgesic activity - pain receptors are unaffected
- Reduces cerebral metabolic rate (CMRO2) in a dose-related manner
- Has neuroprotective effects by preventing lipid peroxidation and mitochondrial damage
Pharmacokinetics
| Parameter | Value |
|---|---|
| Onset (IV) | 1-5 minutes |
| Peak effect (IV) | 3-5 minutes |
| Duration of action | 30-60 minutes |
| Plasma protein binding | 94-98% |
| Volume of distribution | Large (distributes to adipose) |
| Elimination half-life | 1.7-3.5 hours (normal); up to 8 hours in obesity |
| Hepatic extraction ratio | 0.30-0.44 (intermediate) |
| Metabolism | Liver via CYP3A4/CYP3A5 |
| Active metabolite | 1-hydroxymethylmidazolam (alpha-OH midazolam); ~60% potency of parent; accumulates in renal failure |
| Excretion | Urine (as conjugated metabolites) |
| Oral bioavailability | <50% (significant first-pass metabolism) |
Special population pharmacokinetics (Miller's Anesthesia, 10th ed.):
- Obesity: Volume of distribution increases; elimination half-life prolonged to up to 8 hours
- Hepatic cirrhosis: Reduced plasma clearance - dose reduction needed
- Renal impairment: Active metabolite (1-OH midazolam) accumulates - can cause prolonged, profound sedation
- Elderly: Increased sensitivity and longer elimination half-life
- Neonates/premature infants: Lower clearance - use with caution
- Chronic alcohol users (without liver disease): Cross-tolerance - may require higher doses
Clinical Uses
1. Procedural Sedation / Anxiolysis (Conscious Sedation)
The most common use. Provides sedation, anxiolysis, and anterograde amnesia (patient does not remember the procedure).
- Alone provides anxiolysis but not reliable procedural sedation
- Often combined with opioids (fentanyl) or propofol for deeper sedation
- If combined with an opioid: reduce dose by 30% and expect faster, deeper sedation (onset ~1.5 min)
2. Anesthesia Induction & Premedication
- Used as premedicant before general anesthesia to reduce anxiety and provide amnesia
- Can be used for induction, though induction dose is higher
3. ICU Sedation (Mechanical Ventilation)
- Continuous IV infusion for sedation of mechanically ventilated patients
- Caution: metabolite accumulation with prolonged infusions (especially renal failure)
- Recent evidence (PMID: 39827012, 2025 systematic review) suggests other sedatives (propofol, dexmedetomidine) may have better outcomes vs. midazolam infusions in critically ill patients
4. Seizure Termination (Status Epilepticus)
- First-line or second-line for acute seizures, especially when IV access is unavailable
- Intranasal and buccal routes are used in out-of-hospital settings (pediatrics)
- Intrathecal midazolam also reduces spinal cord excitability
5. Prevention of Postoperative Nausea and Vomiting (PONV)
- Meta-analyses support a role in reducing PONV (Miller's Anesthesia)
6. Alcohol Withdrawal
- Used in benzodiazepine-based protocols for alcohol withdrawal seizures
Dosing by Condition
Adults
| Indication | Route | Dose |
|---|---|---|
| Procedural sedation | IV | 0.5-2 mg over 2 min; repeat q2-3 min; usual total: 2.5-5 mg; max 5 mg |
| Premedication | IM | 0.07-0.08 mg/kg (usual: 5 mg) 30-60 min before procedure |
| ICU sedation infusion | IV | 0.02-0.1 mg/kg/hr (titrate to effect) |
| Status epilepticus | IM/IV/IN | 0.1-0.2 mg/kg IV; 10 mg IM; 5-10 mg intranasal |
| Acute seizure (Nayzilam) | Intranasal | 5 mg in one nostril; repeat 5 mg in other nostril after 10 min if needed; max 10 mg/episode |
Pediatric (Harriet Lane Handbook, 23rd ed.)
| Indication | Route | Age | Dose |
|---|---|---|---|
| Procedural sedation | IM | Infant-adolescent | 0.1-0.15 mg/kg; max 10 mg |
| Procedural sedation | IV | 6 mo-5 yr | 0.05-0.1 mg/kg over 2-3 min; max total 6 mg |
| Procedural sedation | IV | 6-12 yr | 0.025-0.05 mg/kg over 2-3 min; max total 10 mg |
| Procedural sedation | IV | 12-18 yr | 0.5-2.5 mg over 2-3 min; max total 10 mg |
| Procedural sedation | PO | ≥6 mo, <16 yr | 0.25-0.5 mg/kg; max 20 mg (younger patients may need 1 mg/kg) |
| Procedural sedation | Intranasal | Infant-adolescent | 0.2-0.3 mg/kg/dose; max 10 mg |
| Mechanical ventilation | IV infusion | Infant/child | 1-2 mcg/kg/min |
| Mechanical ventilation | IV infusion | Neonate <32 wks | 0.5 mcg/kg/min |
| Mechanical ventilation | IV infusion | Neonate ≥32 wks | 1 mcg/kg/min |
| Refractory status epilepticus | IV | ≥2 mo | Load 0.2 mg/kg x1 then infusion 1 mcg/kg/min; titrate q5 min; range 1-18 mcg/kg/min |
| Acute seizure clusters | Intranasal | ≥12 yr (Nayzilam) | 5 mg; repeat in other nostril after 10 min; max 10 mg |
Note: Higher doses required in younger patients (6 mo-5 yr) because of their higher percentage of body water and midazolam's water-soluble properties.
Adverse Effects / Complications
Respiratory
- Respiratory depression (dose-dependent): peak effect at ~3 minutes; significant depression persists for 60-120 minutes
- The faster the IV administration, the more rapid the onset of respiratory depression
- Apnea - uncommon but higher risk at high doses or with concurrent CNS depressants
- Decreased ventilatory response to elevated CO2 (even at sedating doses)
- Additive/synergistic respiratory depression with opioids - can cause apnea
Cardiovascular
- Hypotension - especially when combined with opioids; dose-related
- Blood pressure decrease is modest when midazolam is used alone (benzodiazepines preserve homeostatic reflex mechanisms)
- Bradycardia - reported
- Neonates: can cause severe hypotension if combined with opioids
- Patients with heart failure: slower elimination - higher risk
CNS
- Anterograde amnesia (therapeutic at low doses, adverse at higher doses)
- Paradoxical reactions - restlessness, agitation, disinhibition, combativeness (more common in elderly, pediatrics, and patients with psychiatric disorders)
- Excessive sedation / prolonged sedation - especially in elderly, obese, hepatic impairment, renal impairment
- Delirium in elderly patients (impairs both implicit and relational memory)
- Vivid dreams, sleep disturbance after sedation
Other
- Headache, nausea, emesis, coughing, hiccups (rare)
- Physical dependence and tolerance with chronic use - tolerance appears to decrease receptor binding and function
- Withdrawal syndrome with abrupt discontinuation after prolonged use (anxiety, tremors, seizures)
- Drug interactions (CYP3A4 substrate): markedly increased plasma levels with azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), diltiazem, cimetidine, ranitidine, HIV protease inhibitors - all these are contraindicated or require dose reduction
- Theophylline antagonizes the sedative effects of midazolam
- Prolonged amnesia reported in HIV patients (even at standard conscious sedation doses)
Contraindications
- Narrow-angle glaucoma (absolute)
- Shock (absolute)
- Known hypersensitivity to benzodiazepines
- Concurrent use with HIV protease inhibitors (contraindicated - severe CYP3A4 interaction)
Cautions (Use with Care)
- Congestive heart failure (slower elimination)
- Renal impairment (active metabolite accumulation - adjust dose)
- Hepatic dysfunction (reduced clearance)
- Pulmonary disease / respiratory compromise
- Neonates (lower clearance, risk of hypotension with opioids)
- Elderly (increased sensitivity, prolonged effects, delirium risk)
- Obese patients (prolonged half-life)
- Any concurrent CNS depressant (especially opioids) - reduce dose by 30%
Reversal
Flumazenil (benzodiazepine antagonist) - competitively binds GABA-A benzodiazepine site:
- IV dose: 0.2 mg over 15 seconds; repeat 0.1 mg every 60 seconds; max 1 mg
- Flumazenil reverses sedation/amnesia but does not reliably reverse respiratory depression when opioids are also on board
- In combined opioid + benzodiazepine overdose: give both flumazenil and naloxone
- Flumazenil has a shorter half-life than midazolam - resedation can occur; monitor after reversal
- Contraindicated in patients on long-term benzodiazepines (can precipitate withdrawal seizures)
Drug Interactions Summary
| Interacting Drug/Class | Effect | Action |
|---|---|---|
| Opioids (fentanyl, morphine) | Synergistic CNS/respiratory depression, hypotension | Reduce dose 30%, monitor closely |
| CYP3A4 inhibitors (azoles, macrolides, diltiazem, protease inhibitors) | Increased midazolam levels, prolonged sedation | Avoid or reduce dose significantly |
| Alcohol / CNS depressants | Additive sedation and respiratory depression | Avoid combination |
| Theophylline | Antagonizes sedation | May need higher doses |
| Propofol, ketamine | Additive sedation | Use cautiously in combination |
Key Clinical Pearls
- No analgesia - midazolam does not treat pain; combine with analgesics for painful procedures
- Amnesia is reliable even at low doses - patients may appear awake but won't remember the procedure
- Rate of injection matters - slow IV push (over 2-3 minutes) significantly reduces the risk of respiratory depression and hypotension
- Do not use alone for reliable procedural sedation in emergency settings - combination with fentanyl or other agents is standard practice
- Active metabolite in renal failure - even normal doses can cause profound, prolonged sedation in dialysis patients
- ICU caution - long-term infusions are associated with delirium, withdrawal, and worse outcomes compared to newer agents; current guidelines favor propofol or dexmedetomidine for prolonged ICU sedation (PMID: 39827012)
- Intranasal route is effective for pediatric seizures and provides faster onset than rectal diazepam
Sources: Miller's Anesthesia 10th ed., Goldman-Cecil Medicine, Harriet Lane Handbook 23rd ed., Clinical Gastrointestinal Endoscopy 3rd ed., Rosen's Emergency Medicine, Roberts & Hedges' Clinical Procedures in Emergency Medicine | Recent evidence: Systematic review on ICU sedatives (2025)
Give complete drug reference for Fentanyl as above
Finding Sources
Searching PubMed
fentanyl pharmacology analgesia clinical
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from six major textbooks. Let me compile the full reference.
Fentanyl - Complete Drug Reference
Drug Class & Overview
Fentanyl is a synthetic phenylpiperidine opioid, structurally related to meperidine. It is a pure mu-opioid receptor (MOR) agonist - approximately 80-100 times more potent than morphine. Its exceptionally high lipophilicity makes it ideal for rapid-onset parenteral analgesia, neuraxial use, transdermal delivery, and transmucosal administration.
Brand names: Sublimaze (IV), Duragesic (patch, discontinued), Actiq (lozenge), Fentora (buccal tablet), Nayzilam - note Duragesic generics remain available
Formulations:
- Injection: 50 mcg/mL (1, 2, 5, 10, 20, 50 mL vials)
- SR Transdermal patch: 12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100 mcg/hr (72-hr wear)
- Buccal tablets (Fentora + generics): 100, 200, 400, 600, 800 mcg
- Oral lozenge on stick (Actiq + generics): 200, 400, 600, 800, 1200, 1600 mcg
- Intranasal (off-label using IV formulation with nasal atomizer)
Mechanism of Action
Fentanyl acts as a full agonist at mu-opioid receptors (MOR, OP3) - G-protein coupled receptors (Gi/Go) widely distributed throughout the CNS and peripheral nervous system.
Receptor-level effects:
- MOR subtype-1 (supraspinal): Peripheral and supraspinal analgesia, euphoria, prolactin release
- MOR subtype-2 (spinal): Spinal analgesia, respiratory depression, physical dependence, GI dysmotility, miosis
- Also activates kappa (KOR) and delta (DOR) receptors to a lesser degree
Cellular mechanism:
- Gi/Go protein activation → decreased adenylyl cyclase → decreased cAMP
- Opens inwardly rectifying K+ channels → neuronal hyperpolarization
- Inhibits voltage-gated Ca2+ channels → reduced neurotransmitter release
- Net effect: decreased neuronal excitability and synaptic transmission in pain pathways
CNS distribution of receptors: Highest density in periaqueductal gray, rostral ventromedial medulla, spinal cord dorsal horn (substantia gelatinosa), limbic system, and brain stem respiratory centers.
Key difference from benzodiazepines: Fentanyl has direct analgesic activity and no ceiling effect for analgesia (but has a ceiling for respiratory depression onset that is dose-dependent).
No anxiolytic or amnestic properties at low/analgesic doses - this is why fentanyl must be combined with a sedative/amnestic (e.g., midazolam) when amnesia is desired.
Pharmacokinetics
| Parameter | Value |
|---|---|
| Potency vs morphine | 80-100x more potent |
| IV onset | <30 seconds to 1-2 minutes |
| Peak analgesic effect (IV) | 2-5 minutes (EEG effect: t1/2 ke0 ~6.5 min) |
| Analgesic t1/2 ke0 | 10-20 minutes |
| Duration of action (single IV dose) | 20-40 minutes (clinical); 30-60 minutes |
| Peak respiratory depression (IV) | 5-15 minutes post-injection |
| Plasma protein binding | ~80% |
| Red blood cell uptake | ~40% |
| Volume of distribution | Large; highly lipophilic - extensive tissue distribution |
| Pulmonary first-pass | ~75% transiently taken up by pulmonary endothelium |
| Metabolism | Hepatic: CYP3A4/CYP3A5 - N-dealkylation to norfentanyl (inactive) |
| Norfentanyl appearance | Detectable in plasma within 1.5 min post-IV; in urine up to 48 hr |
| Elimination half-life | ~3-7 hours (context-sensitive half-time increases rapidly with infusion duration) |
| Excretion | Urine (metabolites) |
| Active metabolites | None significant (norfentanyl is inactive) |
| Oral bioavailability | Very low (significant first-pass); transmucosal ~50% |
Critical PK concepts:
- Context-sensitive half-time: Increases rapidly with prolonged infusion - fentanyl's context-sensitive half-time is longer than alfentanil and sufentanil because of its extensive tissue distribution. After short infusions it acts briefly; after prolonged infusions, it accumulates significantly.
- Obesity: Total body weight-based dosing leads to overdose. Use lean body weight for dosing. Accumulated fat reservoir prolongs effect.
- Fever / heat (transdermal): Elevated skin temperature increases fentanyl absorption from patch by ~33% at 40°C - risk of acute overdose.
- CYP3A4 polymorphism affects fentanyl pharmacokinetics considerably.
Clinical Uses
1. Acute Perioperative Analgesia
The most common use. Administered IV before/during surgery to:
- Attenuate cardiovascular responses to laryngoscopy, intubation, skin incision, and surgical stress
- Reduce requirements for inhalational agents (reduces MAC of sevoflurane by ~61% at 3 ng/mL) and propofol by ~50% at 1.5-3 mcg/kg
- Provide intraoperative analgesia as part of balanced anesthesia or TIVA
2. Anesthesia Induction
- Loading dose 2-10 mcg/kg combined with propofol/thiopental and a muscle relaxant
- Fentanyl should be given 5-10 minutes before anticipated painful stimulus (to account for t1/2 ke0)
3. Procedural Sedation & Analgesia (PSA)
- Most commonly used opioid for PSA due to: rapid onset, short duration, no histamine release, favorable cardiovascular profile
- Alone provides analgesia only (no sedation or amnesia at low doses) - combine with midazolam for complete PSA
- Prior to adding a sedative: achieve analgesia with fentanyl first, then titrate sedative - allows accurate sedative dose titration
4. ICU Sedation and Analgesia
- Continuous IV infusion for mechanically ventilated patients
- Used for procedural pain (suctioning, turning) in ICU
- Combination with benzodiazepines increases risk of hemodynamic instability - caution especially in neonates
5. Neuraxial Analgesia (Epidural / Spinal)
- Combined with local anesthetics for epidural labor analgesia and post-op pain
- Intrathecal fentanyl: rapid spinal analgesia for procedures
- Intrathecal fentanyl + bupivacaine is standard for spinal anesthesia
6. Chronic Pain Management (Transdermal / Transmucosal)
- Transdermal patch: Chronic cancer pain and chronic non-cancer pain (opioid-tolerant patients only)
- Buccal tabs / lozenges: Breakthrough cancer pain in patients already on round-the-clock opioid therapy
- Intranasal: Acute and pre-procedural analgesia (especially pediatrics)
- REMS program required for transmucosal formulations
7. Pediatric Neonatal ICU
- Mainstay for sedation and analgesia in neonates during surgery and ICU care
- 2-4 mcg/kg/hr maintains hemodynamic stability in neonates during surgery
Dosing by Condition
Adults
| Indication | Route | Dose | Notes |
|---|---|---|---|
| Procedural analgesia (moderate sedation) | IV | 1 mcg/kg titrated; usual 2-3 mcg/kg total | Titrate q2-4 min |
| Procedural analgesia (deep sedation) | IV | 0.5-2 mcg/kg before sedative agent | |
| Anesthesia induction | IV | 2-10 mcg/kg with induction agent | Give 5-10 min before stimulus |
| Anesthesia maintenance | IV | Bolus 0.5-1 mcg/kg q15-30 min OR infusion 0.02-0.2 mcg/kg/min | |
| Procedural pain (endoscopy) | IV | 50-100 mcg before benzodiazepine | Titrate |
| ICU sedation | IV infusion | 25-200 mcg/hr (titrate) | |
| Premedication | IM | 0.07-0.08 mg/kg (50-100 mcg) 30-60 min before | Usual ~5 mcg/kg |
| Breakthrough cancer pain (buccal tab) | Buccal | Start 100 mcg; repeat once after 30 min if needed; max 2 doses/episode; wait ≥4 hr between episodes | |
| Breakthrough cancer pain (lozenge) | Oral transmucosal | Start 200 mcg; repeat after 15 min completion of first dose; max 2/episode | Must wait ≥4 hr between episodes |
| Chronic pain (tolerant patients) | Transdermal | Start 25 mcg/hr patch q72 hr; only in opioid-tolerant patients | Onset 12-24 hr; steady state in 36-48 hr |
| Acute pain (intranasal) | Intranasal | 1-2 mcg/kg/dose via atomizer | Onset 10-30 min |
Pediatric (Harriet Lane Handbook, 23rd ed.)
| Population | Indication | Route | Dose |
|---|---|---|---|
| Neonate/young infant | Sedation/analgesia | IV | 1-4 mcg/kg/dose q2-4 hr PRN; max 100 mcg/dose |
| Neonate | Continuous infusion | IV | 1-5 mcg/kg/hr (tolerance may develop) |
| Older infant/child | Sedation/analgesia | IV/IM | 1-2 mcg/kg/dose q30-60 min PRN; max 100 mcg/dose |
| Infant/child | Continuous infusion | IV | 1-3 mcg/kg/hr (titrate) |
| ≥1 yr, adolescent | Analgesia (intranasal) | IN | 1-2 mcg/kg/dose; max 100 mcg/dose; q1 hr PRN |
| Opioid-tolerant child ≥2 yr | Chronic pain | Transdermal | 25 mcg/hr patch q72 hr (minimum 60 mg morphine equivalents/24 hr) |
Neonatal note (Barash): Small doses as little as 1-2 mcg/kg can result in significant chest wall rigidity in neonates. Fentanyl + benzodiazepine combinations for >1 week are associated with worse neurodevelopmental outcomes.
Infusion formula (pediatric): 50 × [Desired dose (mcg/kg/hr) / Desired infusion rate (mL/hr)] × weight (kg) = mcg fentanyl in 50 mL fluid
Adverse Effects / Complications
Respiratory
- Respiratory depression - the most clinically significant effect; dose-dependent; peak effect 5-15 minutes after IV dose
- Apnea - especially with rapid administration, high doses, or combinations with CNS depressants
- Depression persists beyond the analgesic period - patients may become pain-free but still have ventilatory depression
- Decreased ventilatory response to hypercapnia and hypoxia
- Bronchospasm - can occur; contraindicated in asthma (per clinical endoscopy guidelines)
- Laryngospasm / glottic spasm - associated with high-dose fentanyl, more prominent in neonates
Musculoskeletal / Airway - UNIQUE TO FENTANYL
- Chest wall rigidity ("wooden chest syndrome") - rigid thoracic muscles making ventilation difficult or impossible
- Mechanism: mu-receptor activation in striatum causing muscle rigidity
- Risk: doses >5-7 mcg/kg IV given rapidly; occurs at lower doses (1-2 mcg/kg) in neonates
- Treatment: Naloxone (may not reliably reverse in severe cases), neuromuscular blockade + intubation; positive pressure ventilation
- Not typically seen at PSA doses (<5 mcg/kg) in adults
Cardiovascular
- Bradycardia - via increased vagal tone (central vagal nucleus stimulation)
- Hypotension - rare at standard analgesic doses in normovolemic patients; more likely with hypovolemia, high doses, or MAO inhibitor combination
- Fentanyl is hemodynamically favorable - even doses of 50 mcg/kg (cardiac surgery) are generally well-tolerated hemodynamically in euvolemic patients
- No histamine release (unlike morphine/meperidine) - advantage in hemodynamically unstable patients
GI
- Nausea and vomiting - less common than with morphine or meperidine, but occurs
- Constipation - opioid-induced (via spinal and peripheral MOR)
- Decreased gastric emptying
- Nasal pruritus - commonly observed; patients frequently attempt to scratch their nose during procedures
CNS
- Sedation / excessive sedation
- Euphoria - reinforcing effect; addiction risk
- Miosis - pinpoint pupils (useful clinical sign in overdose)
- Seizures (with very high doses / toxicity)
Hormonal / Endocrine
- Prolactin release (supraspinal MOR-1)
- Suppression of gonadotropins with chronic use (hypogonadism)
Tolerance and Dependence
- Physical tolerance develops with repeated dosing - dose escalation required to maintain effect
- Physical dependence and withdrawal syndrome with abrupt cessation (anxiety, diaphoresis, tachycardia, GI cramps, myalgias, piloerection)
- Addiction potential - Schedule II controlled substance; high misuse potential
- Opioid-induced hyperalgesia (OIH) - paradoxical increased pain sensitivity with chronic opioid use
Transdermal Patch-Specific Complications
- Delayed onset (12-24 hr) and prolonged offset after removal - unsuitable for acute pain
- Life-threatening overdose if patch is applied to children, opioid-naive patients, or exposed to heat (fever, heating pad, hot tub)
- Fatalities reported with inappropriate use (incorrect patch change frequency, exposing patch to heat)
- Death risk in non-opioid-tolerant patients
Neonatal
- Even small doses (1-2 mcg/kg) → chest wall rigidity, desaturation, need for mechanical ventilation
- Continuous infusions more likely to cause respiratory depression than bolus dosing
- Long-term combo with benzodiazepines (>1 week): worse neurodevelopmental outcomes
Contraindications
- Opioid-naive patients for transdermal/transmucosal formulations (absolute - fatal overdose risk)
- Acute or postoperative pain for transdermal patch (contraindicated - unpredictable absorption)
- Children <2 years for transdermal patch
- Severe respiratory depression / acute bronchial asthma (no respiratory support available)
- Asthma for parenteral fentanyl per some guidelines (risk of bronchospasm)
- Myasthenia gravis (chest wall rigidity risk - contraindication per clinical endoscopy guidelines)
- Known hypersensitivity to fentanyl
- MAO inhibitors within 14 days (risk of serotonin syndrome and severe hypotension)
Cautions / Dose Adjustments
| Condition | Concern | Action |
|---|---|---|
| Hepatic impairment | Reduced CYP3A4 metabolism; prolonged effect | Reduce dose; monitor closely |
| Renal impairment | Norfentanyl excretion delayed (minor - norfentanyl is inactive); adjust for accumulation in severe failure | Use with caution; reduce dose |
| Obesity | Total body weight dosing causes overdose | Use lean body weight for dosing |
| Elderly | Increased CNS sensitivity; decreased clearance | Reduce dose 25-50%; use lower titration increments |
| Neonates/premature infants | Lower clearance; extreme sensitivity to chest wall rigidity | Start at lowest dose; use with caution |
| Hypovolemia | Hypotension with opioid-induced vasodilation | Resuscitate before dosing; reduce dose |
| Raised ICP | CO2 retention from respiratory depression can further increase ICP | Monitor ventilation carefully; titrate slowly |
| Pulmonary disease | Blunted respiratory drive | Reduce dose; have reversal ready |
| Fever (transdermal) | Absorption increases ~33% at 40°C | Monitor for overdose signs; consider patch removal |
Drug Interactions
| Interacting Agent | Effect | Action |
|---|---|---|
| Benzodiazepines (midazolam, lorazepam) | Synergistic respiratory depression + hypotension; additive sedation | Reduce fentanyl dose; monitor closely |
| CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin, diltiazem, verapamil, HIV protease inhibitors, grapefruit juice) | Increased fentanyl plasma levels; prolonged/enhanced effect; overdose risk | Reduce dose; monitor closely; some combinations contraindicated |
| CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) | Decreased fentanyl levels; reduced efficacy; possible withdrawal in opioid-dependent patients | Monitor for reduced effect; may need dose increase |
| MAO inhibitors (phenelzine, tranylcypromine, linezolid, methylene blue) | Serotonin syndrome; severe hypo- or hypertension | Contraindicated; avoid within 14 days |
| Alcohol / CNS depressants (barbiturates, neuroleptics, other opioids) | Additive CNS and respiratory depression | Reduce dose; avoid combination |
| Propofol | Synergistic - reduces MAC equivalents; reduces fentanyl requirements | Combine deliberately (balanced anesthesia); reduce doses of both |
| Monoamine oxidase inhibitors + neuroleptics | Hypotensive adverse events | Avoid combination |
| Neuromuscular blockers | Paralysis reverses chest wall rigidity | Used therapeutically for "wooden chest" |
| Theophylline | May antagonize opioid-mediated effects (minor) | Monitor |
| Nitrous oxide | Synergistic analgesia | Used in balanced anesthesia |
Reversal
Naloxone (competitive mu, kappa, delta antagonist):
- IV: 0.04-0.4 mg; repeat q2-3 min; titrate to effect (avoid precipitating acute withdrawal in opioid-dependent patients)
- Pediatric: 0.01 mg/kg IV/IM/SQ; repeat q2-3 min
- Half-life shorter than fentanyl - re-narcotization (resedation) can occur after naloxone wears off; monitor and repeat dosing or use infusion
- Chest wall rigidity: naloxone may not reliably reverse - add neuromuscular blockade (succinylcholine or rocuronium) + intubation
Opioid Equianalgesic Comparison
| Opioid | Potency vs Morphine | Duration (IV) | Key Feature |
|---|---|---|---|
| Fentanyl | 100x | 20-40 min | High lipophilicity, no histamine release |
| Morphine | 1x (reference) | 3-4 hr | Histamine release, active metabolite |
| Hydromorphone | 5x | 3-4 hr | No histamine release |
| Alfentanil | ~10-20x | 10-15 min | Very short acting |
| Sufentanil | ~500-1000x | 20-45 min | Highest analgesic TI |
| Remifentanil | ~100-200x | 3-10 min | Ester metabolism; no accumulation |
| Carfentanil | ~10,000x | - | Veterinary only; toxicological concern |
Key Clinical Pearls
- Give before the sedative, not after - administer fentanyl first to achieve analgesia, then titrate sedative; prevents over-sedation
- Rate of injection matters critically - slow IV administration (over 3-5 minutes) prevents chest wall rigidity and respiratory depression
- No amnesia - fentanyl provides analgesia but not amnesia; always combine with midazolam or another amnestic for procedures where recall is undesirable
- Respiratory depression outlasts analgesia - monitor for continued respiratory depression after pain relief is achieved
- Transdermal patch: NEVER in opioid-naive patients - fatal overdose risk; requires minimum 60 mg oral morphine equivalents/24 hr tolerance
- Context-sensitive half-time - single doses wear off quickly (30-40 min); infusions accumulate - plan to transition to longer-acting analgesia for post-op pain (e.g., morphine) before ending fentanyl
- Neonatal chest wall rigidity occurs at doses as low as 1-2 mcg/kg - have resuscitation equipment ready
- Preferred opioid for PSA over morphine/meperidine because: no histamine release, rapid onset, short duration, easily reversible, better hemodynamic profile
- Heat warning (patch): Fever, heating pads, saunas, hot tubs all increase patch absorption by up to 33% - risk of fatal overdose
Sources: Barash Clinical Anesthesia 9th ed. | Miller's Anesthesia 10th ed. | Roberts & Hedges' Clinical Procedures in Emergency Medicine | Harriet Lane Handbook 23rd ed. (Johns Hopkins) | Rosen's Emergency Medicine | Clinical GI Endoscopy 3rd ed. | Lippincott Illustrated Reviews: Pharmacology | Goldman-Cecil Medicine | Recent evidence: Systematic review: perioperative fentanyl analgesia in dentistry (2024, PMID: 37837245)
This is a shared conversation. Sign in to Orris to start your own chat.